Phase 2
N=113
Trial of Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial)
Atherosclerosis
Bottom Line
View on ClinicalTrials.gov: NCT00228423 ↗Enrolled (actual)
113
Serious AEs
8.0%
Results posted
Apr 2021
Primary outcome: Primary: Vein Graft Intimal Area — 4.1; 4.5 mm
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Clopidogrel 75 mg daily (Drug); water pill daily (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Ottawa Heart Institute Research Corporation
- Primary completion
- Jun 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Vein Graft Intimal Area |
4.1; 4.5 | — |
| SECONDARY Vein Graft Angiographic Patency |
94.3; 93.2 | — |
| SECONDARY Incidence of Major Adverse Coronary Events Within One Year Following Surgery |
4; 5 | — |
| SECONDARY Incidence of Major Bleeding Events Within One Year Following Surgery |
1; 0 | — |
Summary
The purpose of this study is to determine whether the combination of clopidogrel with aspirin prevents the development of blockages (atherosclerosis) in vein grafts one year after coronary artery bypass surgery (CABG) compared to aspirin alone.
Eligibility Criteria
Inclusion Criteria
- Patients undergoing primary multi-vessel CABG with at least two saphenous vein grafts, with or without the use of cardiopulmonary bypass.
Exclusion Criteria
- Emergency surgery
- Valve surgery
- Redo CABG
- Left ventricle ejection fraction 130 µmol/L
- Preoperative use of clopidogrel (with the exception of the current admission)
- Preoperative use of warfarin; allergy to aspirin or clopidogrel.
- History of cerebrovascular accident
- History of severe liver disease
- Morbid obesity
- Current malignancy
Data sourced from ClinicalTrials.gov (NCT00228423). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.